Back to today’s briefing

Story perspectives

Enzalutamide Cuts Prostate Cancer Death Risk by 40%

10/22/2025

42 6 Full Breakdown

Summary

Story summary

The phase 3 EMBARK trial shows that adding Enzalutamide (Xtandi) to leuprolide reduces death risk by 40% in biochemically recurrent prostate cancer.
After eight years, overall survival was 78.9% with the combination versus 69.5% with leuprolide.
The trial enrolled over 1,000 patients across 17 countries.
Findings were presented at the 2025 ESMO Congress and published in The New England Journal of Medicine.

1 of 1

Story summary

The phase 3 EMBARK trial shows that adding Enzalutamide (Xtandi) to leuprolide reduces death risk by 40% in biochemically recurrent prostate cancer.
After eight years, overall survival was 78.9% with the combination versus 69.5% with leuprolide.
The trial enrolled over 1,000 patients across 17 countries.
Findings were presented at the 2025 ESMO Congress and published in The New England Journal of Medicine.